Headline: CPT code 86362 identifies MOG–IgG1 antibody testing by cell-based assay.

Lead: CPT code 86362 denotes a laboratory assay for myelin oligodendrocyte glycoprotein immunoglobulin G1 (MOG–IgG1) using a cell–based immunofluorescence method on serum. The test is clinically important for distinguishing neuromyelitis optica spectrum disorders from MOG–associated encephalomyelitis and can influence diagnostic and care pathways for inflammatory demyelinating diseases.

Why it matters nationally: As awareness of MOG–IgG1–related disorders grows, demand for specific, validated serologic testing has increased across neurology and neuroimmunology practices. Accurate coding enables appropriate laboratory billing, utilization tracking, and policy development for specialty testing.

Key payers covered: Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

What readers will learn: This publication provides clinical context for CPT code 86362, explains the test method and typical site of service, and summarizes payer coverage scope. Readers will find benchmarks for how the code is used in practice, summaries of relevant policy considerations affecting coverage and prior authorization, and guidance on documentation elements relevant to claims adjudication. The report focuses on national implications for laboratory and neurology stakeholders.

Scope note: Associated taxonomies, ICD-10 mappings, related codes, and payer-specific policy details are addressed in dedicated sections. Data not available in the input are noted where applicable.